Biogen (BIIB) Change in Cash (2009 - 2026)
Biogen (BIIB) recorded quarterly Change in Cash of $392.2 million in Q1 2026, up 145.77% quarter-over-quarter from -$856.8 million in Q4 2025, and up 107.51% on a YoY basis from $189.0 million in Q1 2025.
Biogen (BIIB) Change in Cash (2009 - 2026) Analysis & Trends
Biogen's Change in Cash history runs 18 years deep, the most recent figure standing at $392.2 million for Q1 2026.
- In Q1 2026, Change in Cash rose 107.51% year-over-year to $392.2 million; the TTM figure through Mar 2026 stood at $734.8 million (down 52.11% YoY), while the FY2025 annual figure was $531.6 million, down 61.83% from the prior year.
- Change in Cash was $392.2 million for Q1 2026 at Biogen, up from -$856.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $1.1 billion in Q3 2025 to a low of -$1.3 billion in Q4 2023.
- Historically, Change in Cash has averaged $66.2 million across 5 years, with a median of $47.6 million in 2024.
- Biggest YoY gain for Change in Cash was 718.59% in 2022; the steepest drop was 522.92% in 2022.
- A 5-year view of Change in Cash shows it stood at -$323.5 million in 2022, then slumped by 297.5% to -$1.3 billion in 2023, then jumped by 158.34% to $750.2 million in 2024, then plunged by 214.21% to -$856.8 million in 2025, then soared by 145.77% to $392.2 million in 2026.
- The last three Change in Cash figures came in at $392.2 million (Q1 2026), -$856.8 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -71.45 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | 392.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 392.20 Mn |
| Dec 31, 2025 | -856.80 Mn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 92.20 Mn |
| Mar 31, 2025 | 189.00 Mn |
| Dec 31, 2024 | 750.20 Mn |
| Sep 30, 2024 | -252.10 Mn |
| Jun 30, 2024 | 847.10 Mn |
| Mar 31, 2024 | 47.60 Mn |
| Dec 31, 2023 | -1.29 Bn |
| Sep 30, 2023 | -301.20 Mn |
| Jun 30, 2023 | -276.30 Mn |
| Mar 31, 2023 | -541.10 Mn |
| Dec 31, 2022 | -323.50 Mn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 958.50 Mn |
| Mar 31, 2022 | -502.70 Mn |
| Dec 31, 2021 | 735.40 Mn |
| Sep 30, 2021 | -174.80 Mn |
| Jun 30, 2021 | 510.10 Mn |